Genetics, Genomics, Nanotechnology, and more
Science has interested me for most of my life, but it wasn’t until my first child was born that I shifted from “interested” to “involved.” My eldest daughter was diagnosed with Systemic Onset Juvenile Idiopathic Arthritis (SoJIA – originally called Juvenile Rheumatoid Arthritis, or JRA) when she was 15 months old, which also happened to be about six months into the start of my Consulting company, all while we were in the middle of a very critical Y2K ERP system upgrade and rehosting project. It was definitely a challenging time in my life.
At the time, there was very little research on JRA because it was estimated that only 30,000 children were affected by the disease, and the implication was that funding research would not have a positive ROI. The economics of medical research were eye-opening to me. This was also a few years before major breakthroughs like Enbrel for children.
One of the things that I learned was that this disease could be horribly debilitating. Children often had physical deformities as a result of this disease. Even worse, the systemic type that my daughter has could result in premature death. As a first-time parent, imagining that type of life for your child was extremely difficult.
Luckily, the company I had just started was taking off, so I decided to find ways to make a tangible difference for all children with this disease. We decided to donate 50% of our net profits to fund medical research. Our goal was to fund $1 million in research and find a cure for Juvenile Arthritis within the next 5-7 years.
As someone new to “major gifts” and philanthropy, I quickly learned that some gifting vehicles were more beneficial than others. While most organizations wanted you to start a fund (which we did), the impact tended to be more long-term, supportive, and much less immediate. Later, I met someone passionate, knowledgeable, and successful in her field who showed me a different, better approach (here’s a post that describes it in more detail).
I no longer wanted to blindly give money and hope it was used quickly and properly. Rather, I wanted to treat these donations like investments in a near-term cure. To be successful, I needed to understand research from both medical and scientific perspectives in these areas. That began a new phase in medical research and an independent learning journey in areas where I had limited understanding and expertise.
A lot was happening in Genetics and Genomics at the time (here’s a good explanation of the difference between the two). My interest and efforts in this area led to a position on the Medical and Scientific Advisory Committee with the Arthritis Foundation. Except for me, the other members were talented, successful physicians who were also involved in medical research. We met quarterly, and I asked questions and made suggestions that made a difference. But unlike everyone else on the committee, I needed to study 40+ hours for each call to ensure I understood enough to add value and not be a distraction. Every quarter, I earned my seat at that table, and soon, most of the other members respected me for that (i.e., “not a typical donor”).
A few years later, we did work for a Nanotechnology company (more info here). The Chief Scientist wasn’t interested in explaining what they did until I described some of our research projects on gene expression. He then went into great detail about what they were doing and how he believed it would change what we do in the future. I saw that and agreed. That started my thinking about the potential of leveraging advanced nanotechnology in medicine.
While driving today, I was listening to the “TED Radio Hour” and heard a segment about entrepreneur Richard Resnick. It was exciting because it got me thinking about this again – a topic I haven’t thought about for the past few years (the last time, I was contemplating how new analytics products could be useful in this space).
There are efforts today with custom, personalized medicines that target only specific genes for a specific outcome. The genetic modifications being performed on plants today will likely be performed on humans in the near future (I would guess within 10-15 years as gene editing becomes more mainstream), possibly even performed by some type of robots. Because the body is an incredibly adaptive organism, it may be very challenging to implement anything consequential that is consistently safe and effective long-term. But that day will come.
It’s not a huge leap from genetically modified “treatment cells” to true nanotechnology (not just extremely small particles). Just think, machines that can be designed to work independently within us to do what they are programmed to do and, more importantly, identify and understand adaptations (i.e., artificial intelligence) as they occur and alter their approach and treatment plan accordingly based on findings and changes. This is extremely exciting. From my perspective, being able to do things that positively impact the quality of life for children and their families is a worthy goal.
My advice is to keep learning, stay open-minded, and do what you can to make a difference. You will never know what is possible unless you try. It will also be interesting to see how technologies evolve and work together to create an even greater impact.
Where Ideas, Experiences, and Lessons Learned Intersect 